Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm Therapeutics Announces Pricing of Initial Public Offering
Karyopharm Therapeutics Announces Pricing of Initial Public Offering NATICK, Mass., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing novel first-in-class drugs directed against nuclear transport targets for the treatment of
View HTML
Toggle Summary Karyopharm Therapeutics Announces Oral Presentations at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) XPO1 Antagonists in preclinical models of Autoimmune Disease
Karyopharm Therapeutics Announces Oral Presentations at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) XPO1 Antagonists in preclinical models of Autoimmune Disease Natick, Mass . – October 22, 2013 – Karyopharm Therapeutics Inc.
View HTML
Toggle Summary Karyopharm Therapeutics Files Registration Statement for Proposed Initial Public Offering
Karyopharm Therapeutics Files Registration Statement for Proposed Initial Public Offering Natick, Mass. – October 7, 2013 – Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing novel first-in-class drugs directed against nuclear transport targets for the
View HTML
Toggle Summary Karyopharm Therapeutics Announces Appointment of Garen Bohlin to Board of Directors
Karyopharm Therapeutics Announces Appointment of Garen Bohlin to Board of Directors Natick, Mass . – October 3, 2013 – Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing novel first-in-class drugs directed against nuclear transport targets for the treatment
View HTML
Toggle Summary Karyopharm Therapeutics Announces Preclinical Data for Selinexor (KPT-330) in Acute Myeloblastic Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Models at FASEB Science Research Conferences
– New results show that Selective Inhibitor of Nuclear Export (SINE) compounds kill leukemia initiating cells while sparing normal stem cells in preclinical models –
View HTML
Toggle Summary Karyopharm Therapeutics Secures $19 Million in Series B Financing Extension
- Additional funds to expand the clinical development of Selinexor (KPT-330), including planned Phase 2/3 clinical trials - - Total Series B commitment exceeds $67 million –
View HTML
Toggle Summary Karyopharm Therapeutics Initiates a Phase 1b Food-Effect Clinical Trial with the Novel Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Advanced Sarcomas
Karyopharm Therapeutics Initiates a Phase 1b Food-Effect Clinical Trial with the Novel Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Advanced Sarcomas Natick, Mass – July 31, 2012 – Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company
View HTML
Toggle Summary Karyopharm Therapeutics Presents Clinical Data for Selinexor (KPT-330), a First-in-Class Selective Inhibitor of Nuclear Export (SINE), in Solid Tumors at the 2013 ASCO Annual Meeting
Karyopharm Therapeutics Presents Clinical Data for Selinexor (KPT-330), a First-in-Class Selective Inhibitor of Nuclear Export (SINE), in Solid Tumors at the 2013 ASCO Annual Meeting Natick, Mass . – June 2, 2013 – Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport
View HTML
Toggle Summary Karyopharm Therapeutics to Present New Data on Selective Inhibitor of Nuclear Export (SINE), KPT-330, at 2013 EHA Congress
Karyopharm Therapeutics to Present New Data on Selective Inhibitor of Nuclear Export (SINE), KPT-330, at 2013 EHA Congress Natick, Mass . – May 28, 2013 – Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced that data for its lead compound KPT-330
View HTML
Toggle Summary Karyopharm Therapeutics Raises $48.2 Million in Series B Financing
-Will fund development of lead compound KPT-330 through pivotal studies in two oncology indications -
View HTML